{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:44:51Z","timestamp":1758638691997},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,2,10]],"date-time":"2017-02-10T00:00:00Z","timestamp":1486684800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s00228-017-2210-x","type":"journal-article","created":{"date-parts":[[2017,2,10]],"date-time":"2017-02-10T02:39:28Z","timestamp":1486694368000},"page":"517-523","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review"],"prefix":"10.1007","volume":"73","author":[{"given":"Paul","family":"de Boissieu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Kanagaratnam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Morel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Dram\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Trenque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,10]]},"reference":[{"key":"2210_CR1","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jocd.2008.02.002","volume":"11","author":"PD Delmas","year":"2008","unstructured":"Delmas PD (2008) Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases. J Clin Densitom 11:325\u2013338","journal-title":"J Clin Densitom"},{"key":"2210_CR2","unstructured":"U.S. Food and Drug Administration (2010) Press announcements: FDA approves new injectable osteoporosis treatment for postmenopausal women. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm214150.htm Accessed 02 Jan 2017"},{"key":"2210_CR3","unstructured":"European Medicines Agency (2010) Prolia. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/001120\/human_med_001324.jsp&mid=WC0b01ac058001d124 . Accessed 02 Jan 2017"},{"key":"2210_CR4","unstructured":"U.S. Food and Drug Administration (2010) Press announcements: FDA approves Xgeva to help prevent cancer-related bone injury. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm234346.htm Accessed 02 Jan 2017"},{"key":"2210_CR5","unstructured":"European Medicines Agency (2011) Xgeva. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002173\/human_med_001463.jsp&mid=WC0b01ac058001d124 . Accessed 02 Jan 2017"},{"key":"2210_CR6","unstructured":"European Medicines Agency (2011) Assessment report for Xgeva. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002173\/WC500110384.pdf . Accessed 02 Jan 2017"},{"key":"2210_CR7","unstructured":"U.S. Food and Drug Administration (2010) Prolia risk evaluation and mitigation strategy. http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandproviders\/UCM214383.pdf . Accessed 02 Jan 2017"},{"key":"2210_CR8","unstructured":"U.S. Food and Drug Administration (2013) Xgeva (denosumab) label. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125320s094lbl.pdf . Accessed 02 Jan 2017"},{"key":"2210_CR9","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","volume":"29","author":"CH Van Poznak","year":"2011","unstructured":"Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS et al (2011) American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29:1221\u20131227","journal-title":"J Clin Oncol"},{"key":"2210_CR10","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.oooo.2013.10.010","volume":"117","author":"M Schiodt","year":"2014","unstructured":"Schiodt M, Reibel J, Oturai P, Kofod T (2014) Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system. Oral Surg Oral Med Oral Pathol Oral Radiol 117:204\u2013213","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"2210_CR11","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.joms.2008.02.012","volume":"66","author":"L Junquera","year":"2008","unstructured":"Junquera L, Gallego L (2008) Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant? J Oral Maxillofac Surg 66:1516\u20131517","journal-title":"J Oral Maxillofac Surg"},{"key":"2210_CR12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.joms.2008.09.031","volume":"67","author":"H Mawardi","year":"2009","unstructured":"Mawardi H, Treister N, Richardson P, Anderson K, Munshi N, Faiella RA et al (2009) Sinus tracts\u2014an early sign of bisphosphonate-associated osteonecrosis of the jaws? J Oral Maxillofac Surg 67:593\u2013601","journal-title":"J Oral Maxillofac Surg"},{"key":"2210_CR13","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B et al (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update. J Oral Maxillofac Surg 72:1938\u20131956","journal-title":"J Oral Maxillofac Surg"},{"key":"2210_CR14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1601-0825.2012.01903.x","volume":"18","author":"A Bedogni","year":"2012","unstructured":"Bedogni A, Fusco V, Agrillo A, Campisi G (2012) Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw (BRONJ). Oral Dis 18:621\u2013623","journal-title":"Oral Dis"},{"key":"2210_CR15","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.bjoms.2014.04.009","volume":"52","author":"A Bedogni","year":"2014","unstructured":"Bedogni A, Fedele S, Bedogni G, Scoletta M, Favia G, Colella G et al (2014) Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease. Br J Oral Maxillofac Surg 52:603\u2013608","journal-title":"Br J Oral Maxillofac Surg"},{"key":"2210_CR16","unstructured":"U.S. Food and Drug Administration: The drug development process\u2014step 3: clinical research. http:\/\/www.fda.gov\/ForPatients\/Approvals\/Drugs\/ucm405622.htm . Accessed 02 Jan 2017"},{"key":"2210_CR17","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/S0140-6736(15)00975-7","volume":"386","author":"M Gnant","year":"2015","unstructured":"Gnant M, all ABCSG-18 investigators (2015) Denosumab and fracture risk in women with breast cancer\u2014author\u2019s reply. Lancet 386:2057\u20132058","journal-title":"Lancet"},{"key":"2210_CR18","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264\u2013269","journal-title":"Ann Intern Med"},{"key":"2210_CR19","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"2210_CR20","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","volume":"361","author":"MR Smith","year":"2009","unstructured":"Smith MR, Egerdie B, Toriz NH, Feldman R, Tammela TLJ, Saad F et al (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745\u2013755","journal-title":"N Engl J Med"},{"key":"2210_CR21","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body J-J, Steger GG, Tonkin K, de Boer RH et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132\u20135139","journal-title":"J Clin Oncol"},{"key":"2210_CR22","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1007\/s00198-010-1378-z","volume":"22","author":"DL Kendler","year":"2011","unstructured":"Kendler DL, McClung MR, Freemantle N, Lillestol M, Moffett AH, Borenstein J et al (2011) Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 22:1725\u20131735","journal-title":"Osteoporos Int"},{"key":"2210_CR23","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125\u20131132","journal-title":"J Clin Oncol"},{"key":"2210_CR24","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813\u2013822","journal-title":"Lancet"},{"key":"2210_CR25","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1210\/jc.2012-1569","volume":"97","author":"E Orwoll","year":"2012","unstructured":"Orwoll E, Teglbj\u00e6rg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL et al (2012) A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 97:3161\u20133169","journal-title":"J Clin Endocrinol Metab"},{"key":"2210_CR26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","volume":"379","author":"MR Smith","year":"2012","unstructured":"Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B et al (2012) Denosumab and bone metastasis-free survival in men with castration-resistant prostate cancer: results of a global phase 3, randomised, placebo-controlled trial. Lancet 379:39\u201346","journal-title":"Lancet"},{"key":"2210_CR27","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","volume":"121","author":"C Recknor","year":"2013","unstructured":"Recknor C, Czerwinski E, Bone HG, Bonnick SL, Binkley N, Palacios S et al (2013) Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol 121:1291\u20131299","journal-title":"Obstet Gynecol"},{"key":"2210_CR28","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1210\/jc.2013-4175","volume":"99","author":"T Nakamura","year":"2014","unstructured":"Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T, Gorai I et al (2014) Clinical trials express: fracture risk reduction with denosumab in japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab 99:2599\u20132607","journal-title":"J Clin Endocrinol Metab"},{"key":"2210_CR29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","volume":"58","author":"C Roux","year":"2014","unstructured":"Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A et al (2014) Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone 58:48\u201354","journal-title":"Bone"},{"key":"2210_CR30","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4103\/2230-8210.146871","volume":"19","author":"S Pitale","year":"2015","unstructured":"Pitale S, Thomas M, Rathi G, Deshmukh V, Kumar P, Reddy S et al (2015) A randomized placebo-controlled trial of the efficacy of denosumab in Indian postmenopausal women with osteoporosis. Indian J Endocrinol Metab 19:148\u2013154","journal-title":"Indian J Endocrinol Metab"},{"key":"2210_CR31","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","volume":"386","author":"M Gnant","year":"2015","unstructured":"Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R et al (2015) Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386:433\u2013443","journal-title":"Lancet"},{"key":"2210_CR32","unstructured":"Office of the Law Revision Counsel (1938) United States Code, New drugs (sec. 505), Public laws - Ch. 675. http:\/\/uscode.house.gov\/statviewer.htm?volume=52&page=1059# . Accessed 02 Jan 2017"},{"key":"2210_CR33","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","volume":"65","author":"American Association of Oral and Maxillofacial Surgeons","year":"2007","unstructured":"American Association of Oral and Maxillofacial Surgeons (2007) Position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65:369\u2013376","journal-title":"J Oral Maxillofac Surg"},{"key":"2210_CR34","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.amjmed.2010.04.033","volume":"123","author":"S Fedele","year":"2010","unstructured":"Fedele S, Porter SR, D\u2019Aiuto F, Aljohani S, Vescovi P, Manfredi M et al (2010) Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 123:1060\u20131064","journal-title":"Am J Med"},{"key":"2210_CR35","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0278-2391(09)01877-1","volume":"67","author":"SL Ruggiero","year":"2009","unstructured":"Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B et al (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20142009 update. J Oral Maxillofac Surg 67:2\u201312","journal-title":"J Oral Maxillofac Surg"},{"key":"2210_CR36","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","volume":"22","author":"S Khosla","year":"2007","unstructured":"Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479\u20131491","journal-title":"J Bone Miner Res"},{"key":"2210_CR37","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1016\/j.joms.2009.07.097","volume":"67","author":"G Colella","year":"2009","unstructured":"Colella G, Campisi G, Fusco V (2009) American Association of Oral and Maxillofacial Surgeons Position Paper: bisphosphonate-related osteonecrosis of the jaws\u20142009 update: the need to refine the BRONJ definition. J Oral Maxillofac Surg 67:2698\u20132699","journal-title":"J Oral Maxillofac Surg"},{"key":"2210_CR38","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1080\/14740338.2016.1177021","volume":"15","author":"V Fusco","year":"2016","unstructured":"Fusco V, Santini D, Armento G, Tonini G, Campisi G (2016) Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology. Expert Opin Drug Saf 15:925\u2013935","journal-title":"Expert Opin Drug Saf"},{"key":"2210_CR39","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","volume":"23","author":"F Saad","year":"2012","unstructured":"Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT et al (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341\u20131347","journal-title":"Ann Oncol"},{"key":"2210_CR40","unstructured":"Schulz KF, Altman DG, Moher D, CONSORT Group (2010) CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials11:32."},{"key":"2210_CR41","unstructured":"CONSORT Group. CONSORT Outcomes 6a. http:\/\/www.consort-statement.org\/checklists\/view\/32-consort\/80-outcomes . Accessed 02 Jan 2017"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-017-2210-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-017-2210-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-017-2210-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T06:14:54Z","timestamp":1498371294000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-017-2210-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,10]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["2210"],"URL":"https:\/\/doi.org\/10.1007\/s00228-017-2210-x","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,10]]}}}